Shares of Innovent Biologics (HKG:1801) are soaring 18.95% in intraday trading on Thursday, following the release of the company's impressive 2024 financial results. The surge in stock price reflects investors' positive reaction to the drugmaker's significant improvement in financial performance.
According to the company's filing with the Hong Kong stock exchange on Wednesday, Innovent Biologics reported a substantial narrowing of its attributable loss to 94.6 million yuan in 2024, down 91% from 1.03 billion yuan in the previous year. The loss per share decreased dramatically to 0.06 yuan from 0.66 yuan a year earlier, significantly outperforming analysts' expectations of a 0.38 yuan loss per share as estimated by Visible Alpha.
Perhaps most notably, Innovent Biologics achieved a remarkable 52% year-on-year increase in revenue, reaching 9.42 billion yuan compared to 6.21 billion yuan in 2023. This figure also surpassed Visible Alpha analysts' forecast of 8.36 billion yuan. The combination of narrowing losses and robust revenue growth has clearly boosted investor confidence, driving the stock's sharp rise in today's trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.